KDR and metabolic dysfunction-associated steatohepatitis: Coulon et al. (2013) reported that blockade of VEGFR2 attenuates hepatic steatosis in two rodent models of non-alcoholic steatohepatitis, both in a preventive and therapeutic setting. In zebrafish larvae, hepatic parenchymal cells expressed minimal levels of VEGF receptor genes regardless of ethanol exposure. Thus, the inhibition of ethanol-induced steatosis by ZM treatment is likely to be secondary to the attenuation of angiogenesis and fibrogenesis. Our study of cloche mutants provided direct evidence to show that fibrogenesis and steatosis could be uncoupled from angiogenesis.